You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High-grade neuroendocrine tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site Trial in San

Not yet recruiting
  • Neuroendocrine Tumors
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Feb 17, 2023

Neuroendocrine Tumor of Pancreas (Disorder), Neuroendocrine Tumor Grade 1 Trial in Marseille (Radiofrequency ablation)

Recruiting
  • Neuroendocrine Tumor of Pancreas (Disorder)
  • Neuroendocrine Tumor Grade 1
  • Radiofrequency ablation
  • Marseille, France
    Institut Paoli Calmettes
Jan 5, 2022

High Grade Neuroendocrine Tumors Trial in Saint Louis (Cabozantinib, Blood for plasma biomarkers, Tissue biopsy)

Recruiting
  • High Grade Neuroendocrine Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 11, 2021

Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma Trial in Xiamen, Harbin (Chidamide, Sintilimab)

Recruiting
  • Neuroendocrine Tumors
  • +3 more
  • Xiamen, Fujian, China
  • +1 more
Nov 22, 2021

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Neuroendocrine Tumors Trial in Philadelphia, Houston (Pembrolizumab)

Completed
Has Results
  • Neuroendocrine Tumors
  • Philadelphia, Pennsylvania
  • +1 more
Feb 16, 2021

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Recruiting
  • NSCLC
  • +6 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Dec 20, 2022

Neuroendocrine Tumor Trial in Beijing (Sintilimab, IBI310, Surufatinib)

Recruiting
  • Neuroendocrine Neoplasm
  • Beijing, Beijing, China
  • +1 more
Dec 7, 2021

Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder Trial in United States (Ipilimumab, Nivolumab)

Recruiting
  • Genitourinary Cancer
  • +7 more
  • La Jolla, California
  • +5 more
Jul 5, 2022

SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

Recruiting
  • SCLC
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) Trial in San Francisco, Boston, New York (Pembrolizumab, Irinotecan,

Completed
Has Results
  • High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
  • San Francisco, California
  • +2 more
Dec 5, 2022

Surufatinib in G3 Neuroendocrine Tumors

Not yet recruiting
  • Neuroendocrine Tumor Grade 3
  • (no location specified)
Aug 2, 2023

Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1 Trial in Iowa City ([212Pb] VMT-a-NET,

Recruiting
  • Neuroendocrine Tumors
  • +4 more
  • [212Pb] VMT-α-NET
  • [203Pb] VMT-α-NET SPECT/CT
  • Iowa City, Iowa
    Holden Comprehensive Cancer Center at the University of Iowa
Nov 30, 2023

Pancreatic Neuroendocrine Tumor G2 Trial (Octreotide LAR)

Completed
  • Pancreatic Neuroendocrine Tumor G2
  • Octreotide LAR
  • (no location specified)
Oct 17, 2023

Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1 Trial ([203Pb]VMT-a-NET, SPECT/CT)

Enrolling by invitation
  • Neuroendocrine Tumor Grade 2
  • Neuroendocrine Tumor Grade 1
  • Iowa City, Iowa
    The University of Iowa
Dec 9, 2022

Right-sided Hemicolectomy for Chldren With High-risk

Recruiting
  • Neoplasms
  • Appendix Cancer
    • Amsterdam-Zuidoost, Netherlands
      Amsterdam UMC
    Jun 23, 2023

    Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,

    Not yet recruiting
    • Advanced Gastroenteropancreatic Neuroendocrine Tumor
    • Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
    • long-acting Octreotide.
    • (no location specified)
    May 22, 2023

    Neuroendocrine Tumors Trial in Lexington (Telotristat (Low-Dose), Telotristat (High-Dose))

    Recruiting
    • Neuroendocrine Tumors
    • Telotristat (Low-Dose)
    • Telotristat (High-Dose)
    • Lexington, Kentucky
      Markey Cancer Center
    Nov 10, 2022

    Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

    Recruiting
    • Neuroendocrine Tumor Grade 3
    • +2 more
    • Tianjin, Tianjin, China
      Rui Liu
    Nov 17, 2022

    Small-cell Lung Cancer, Neuroendocrine Carcinoma Trial (Iadademstat, Paclitaxel)

    Not yet recruiting
    • Small-cell Lung Cancer
    • Neuroendocrine Carcinoma
    • (no location specified)
    Jun 13, 2022

    Pancreatic Neuroendocrine Tumors, WHO Grade I-II Trial in Oslo (Radio frequency ablation)

    Recruiting
    • Pancreatic Neuroendocrine Tumors, WHO Grade I-II
    • Radio frequency ablation
    • Oslo, Norway
      Oslo University Hospital
    Feb 7, 2022

    Gastroenteropancreatic Neuroendocrine Tumor Trial in Stanford (Lutathera, Gallium 68 Dotatate, Computed Tomography (CT))

    Suspended
    • Gastroenteropancreatic Neuroendocrine Tumor
    • Stanford, California
      Stanford Cancer Institute Palo Alto
    Sep 21, 2022

    Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC) Trial in Spain (177Lu-Dotatate, Nivolumab)

    Recruiting
    • Neuroendocrine Tumours (NET)
    • Neuroendocrine Carcinomas (NEC)
    • Santiago De Compostela, Galicia, Spain
    • +4 more
    Aug 1, 2022

    Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors Trial in Little Rock, Buffalo, Philadelphia (Capecitabine Oral Product,

    Recruiting
    • Neuroendocrine Tumor Grade 2
    • Neuroendocrine Tumors
    • Capecitabine Oral Product
    • +2 more
    • Little Rock, Arkansas
    • +2 more
    Aug 11, 2022

    Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas Trial (KT-253)

    Not yet recruiting
    • Myeloid Malignancies
    • +3 more
    • (no location specified)
    Mar 22, 2023